Ibogaine for Executive Burnout: What's Actually True and What's Marketing
Searches for "ibogaine executive burnout" have been climbing, and the framing deserves a direct answer before anything else: burnout is not a medical diagnosis. The World Health Organization classified it in ICD-11 (2019) explicitly as an "occupational phenomenon," and was specific that it "should not be applied to describe experiences in other areas of life." It sits in the same chapter as factors influencing health status, not alongside depression or PTSD as a diagnosable disorder. That single fact changes how you should evaluate anything claiming to "treat" it.
What Burnout Actually Is, Clinically
The working definition researchers use comes from Christina Maslach and Michael Leiter's Maslach Burnout Inventory, the most validated burnout measure in use for more than three decades. It has three dimensions, and the clinical convention is that all three need to be present: emotional exhaustion, cynicism or mental distance from the work, and a reduced sense of professional effectiveness. One or two of these without the third is usually something else, often depression, anxiety, or plain overwork that better sleep and boundaries would fix.
That distinction matters because depression and anxiety are conditions with real diagnostic criteria, and real ibogaine research exists for both. Burnout, by the WHO's own definition, is not. If you're experiencing persistent low mood, loss of interest in things you used to care about, or anxiety that doesn't resolve with rest, those symptoms deserve an actual diagnostic evaluation, not a label that conveniently avoids one.
Is There Any Ibogaine Research on Burnout Specifically? No.
We looked. There is no published research, no case series, no clinical trial, testing ibogaine for burnout as its own outcome. What exists is adjacent, not equivalent:
- A randomized controlled trial published in PLOS Medicine tested psilocybin-assisted group psychotherapy against mindfulness-based stress reduction in 25 healthcare workers with depression and burnout symptoms following COVID-19. This is real clinical research, with a control group, on a different psychedelic compound, in a different population, with depression as a co-occurring diagnosis rather than burnout treated in isolation.
- A separate study examined burnout measures in emergency medical service workers following a psychedelic experience, again not ibogaine specifically, and observational rather than a controlled design.
- Everything else in circulation, including most of what you'll find marketed directly at executives, is anecdotal: self-reports from microdosing, personal essays, and clinic marketing copy that uses "burnout" because it sounds better in an ad than "I think I might be depressed but don't want that on any record."
That last sentence isn't cynicism. It's worth saying plainly because it's probably part of why you're reading this page.
The Honest Reason Executives Search for "Burnout" Instead of "Depression"
There are real, understandable reasons a senior executive researching psychedelic treatment prefers the word burnout over depression or anxiety. Burnout implies a response to circumstances (too much work, too little recovery) rather than a clinical condition attached to you personally. It carries less stigma in a boardroom. It doesn't raise the same questions in a background check, a board evaluation, or a conversation with investors. None of that makes the underlying distress less real. It does mean the term itself is sometimes chosen for what it avoids saying, not for diagnostic accuracy.
If part of what's driving interest in ibogaine specifically, versus conventional psychiatric treatment, is the appeal of an intensive, time-limited, international, and more private experience rather than an ongoing domestic treatment relationship with a paper trail, that's worth being honest with yourself about. It's a legitimate preference. It is not the same thing as burnout being a condition ibogaine has been shown to treat.
What We'd Actually Recommend Looking Into
If your symptoms involve persistent low mood, anhedonia, or a sense that nothing you accomplish matters anymore, read our depression page, which covers some of the strongest ibogaine evidence on this entire site. If what dominates is a racing mind, dread, or an inability to switch off even when the circumstances causing stress are temporarily absent, our anxiety page is the more honest starting point, though the evidence there is thinner. If alcohol or stimulants have become part of how you're coping with the workload, that's worth naming to yourself and to any clinician directly, our alcohol addiction and cocaine addiction pages cover ibogaine's actual evidence base there.
None of these labels are about judgment. They're about matching what you're actually experiencing to where the real clinical evidence lives, rather than to whichever word feels safest to say out loud.
If You Still Pursue Ibogaine Treatment
The cardiac risk conversation applies to you exactly as it applies to anyone else, arguably more so if years of high-stress work, poor sleep, and travel have gone unmanaged. Read our page on QT prolongation risk before any consultation, and ask any clinic the same questions anyone should ask: what does their cardiac screening actually involve, who is present and qualified during the dosing window, and what integration support exists after you fly home and the same job, the same inbox, and the same board meetings are waiting for you exactly as you left them.
Treatment doesn't change your circumstances. Whatever you're actually dealing with deserves an honest diagnosis first, whatever word turns out to be the accurate one.